Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.75 |
| ▸ | RAB9A | P51151 | 9/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.75 |
| ▸ | HPGD | P15428 | 6/20 | 0.75 |
| ▸ | TP53 | P04637 | 5/20 | 0.75 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.75 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.75 |
| ▸ | RELA | Q04206 | 3/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.75 |
| ▸ | TSHR | P16473 | 2/20 | 0.75 |
| ▸ | PKM | P14618 | 3/20 | 0.70 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.60 |
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 6/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18715523 | 1.00 | NPC1 (0.75) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL2478174 | 0.95 | NPC1 (0.68) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL7852530 | 0.93 | NPC1 (0.71) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL8603235 | 0.89 | SLC2A1 (0.76) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL16281922 | 0.89 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL419326 | 0.89 | NPC1 (0.71) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL4186413 | 0.86 | NPC1 (0.94) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL16281928 | 0.86 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL20445328 | 0.86 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL2324292 | 0.86 | NPC1 (0.78) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975416-B2 | Antibacterial compounds | SUMMIT CORPORATION PLC (GB) | 2015-03-10 | — | — | US | claimed |
| EP-2373631-B1 | ANTIBACTERIAL COMPOUNDS | SUMMIT CORP PLC (GB) | 2015-02-25 | — | — | EP | claimed |
| US-9763925-B2 | Antibacterial compounds | SUMMIT THERAPEUTICS PLC (GB) | 2017-09-19 | — | — | US | disclosed |
| EP-3095783-A1 | ANTIBACTERIAL COMPOUNDS | Summit Corporation Plc (GB) | 2016-11-23 | — | — | EP | disclosed |
| US-20160184283-A1 | ANTIBACTERIAL COMPOUNDS | SUMMIT (OXFORD) LIMITED (GB) | 2016-06-30 | — | — | US | disclosed |
| US-9314456-B2 | Antibacterial compounds | SUMMIT THERAPEUTICS PLC (GB) | 2016-04-19 | — | — | US | disclosed |
| EP-2907813-A1 | Antibacterial Compound | Summit Corporation Plc (GB) | 2015-08-19 | — | — | EP | disclosed |
| US-20150150861-A1 | ANTIBACTERIAL COMPOUNDS | SUMMIT (OXFORD) LIMITED (GB) | 2015-06-04 | — | — | US | disclosed |
| US-8975416-B2 | Antibacterial compounds | SUMMIT CORPORATION PLC (GB) | 2015-03-10 | — | — | US | disclosed |
| EP-2373631-B1 | ANTIBACTERIAL COMPOUNDS | SUMMIT CORP PLC (GB) | 2015-02-25 | — | — | EP | disclosed |
| US-20120020950-A1 | ANTIBACTERIAL COMPOUNDS | SUMMIT CORPORATION PLC | 2012-01-26 | — | — | US | disclosed |
| EP-2373631-A2 | ANTIBACTERIAL COMPOUNDS | Summit Corporation Plc (GB) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010063996-A2 | ANTIBACTERIAL COMPOUNDS | SUMMIT CORPORATION PLC (GB) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184283-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, RPN2, ALPI | NPC1 512/4885RAB9A 1670/4885SMN1; SMN2 2597/4885 |
| US-20120020950-A1 | ANTIBACTERIAL COMPOUNDS | RPN2, MRPL21, ALPI | NPC1 509/4885RAB9A 1673/4885SMN1; SMN2 2666/4885 |
| US-20150150861-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, RPN2, ALPI | NPC1 512/4885RAB9A 1670/4885SMN1; SMN2 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.